IsoRay completes Cs-131 brachytherapy seeds feasibility study for breast cancer treat
 

IsoRay, Inc. announced, today, it has completed an initial feasibility study, which demonstrates the ability to use its patented Cesium-131 (Cs-131) brachytherapy seeds (internal radiation therapy) in accelerated partial breast irradiation (APBI) for breast cancer treatment.

More...